Molecular Templates (MTEM) released its first quarter results on Friday, May 14, 2021. The company reported net earnings of $-0.51 per share for the first quarter ending March 31, 2021. Earnings for this past quarter declined 6 percent compared to the same period a year ago.
Molecular Templates, Inc. is headquartered in Austin, Texas. Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies.
Molecular Templates' revenue decreased 8 percent over the past trailing twelve-month period versus the previous twelve-month period. Operating margins decreased to 817.67% over the same period. Net earnings for past trailing twelve months were $-109.68 million, down 29% from the prior year.
Moving on to the balance sheet, Molecular Templates' cash levels jumped 187% for the first quarter over the same period last year. Overall liquidity of the balance sheet, as measured by the current ratio, decreased 3.58% this past year. The current ratio for Molecular Templates now stands at 2.73. The company increased shares outstanding by 22.71%.
Shares of MTEM are currently trading around $7.86. In terms of valuation, the stock is trading at a price to book ratio of 3.81.
_____
This article was written by Value Investing News (https://www.valueinvestingnews.com) on Saturday, May 15, 2021.